Of doxorubicin

Kruizinga, W., and Hillen, F. C. (1989b). A comparative study on antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin administered as bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat, Cancer Chemother. Pharmacol. 24, 341-348. 

A. (1990b). Effect of lipid composition on the in vivo integrity of doxorubicin-containing liposomes. Two pathways for sustained release of doxorubicin. Submitted. 

Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins JE, Earooque A, Chandraiah G, Jain AK, Misra A, Lecommandoux S (2010) The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(y-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 31(10) 2882... 

Bidwell GL, Fokt 1, Priebe W et al (2007) Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73 620-631... 

The delivery of doxorubicin to the SI80 sarcoma (tumor) in mice, using niosomes as a carrier, has been studied by Rogerson [168]. Much higher tumor drug levels were reported with niosomes prepared using the nonionic surfactant I and 50% cholesterol than with free... 

Figure 7.46 Fluorescence quenching of doxorubicin by DNA [597] (a) doxorubicin in aqueous solution, quenched immediately on addition of DNA (b) doxorubicin fluorescence not affected by vesicles (c) Doxorubicin preequihbrated with vesicles, and then subjected to DNA. The fraction bound to the outer membrane leaflet is immediately quenched by the DNA. (d) Same as (c), but multilamellar vesicles used. The left arrow represents a 5-min interval and applies to the first three cases the right arrow represents 30-min interval and applies to (d) only. [Reprinted from Ronit Regev and Gera D. Eylan, Biochemical Pharmacology, vol. 54, 1997, pp. 1151-1158. With permission from Elsevier Science.]...

Regev, R. Eytan, G. D., Flip-flop of doxorubicin across erythrocyte and lipid membranes, Biochem. Pharmacol. 54, 1151-1158 (1997). 

D. D. Breimer. Specificity of doxorubicin versus rhodamine-123 in assessing P- glycoprotein functionality in the LLC-PK1, LLC-PK1 MDR1 and Caco-2 cell lines, Ear. J. Pharm. Sci. 2000, 11, 207-214... 

Fig. 20.10. Enhancement of doxorubicin cytotoxicity in LoVo-resistant cells by verapamil and analogues. (Adapted from Ref. [77]). The results are expressed as fold increase in cytotoxicity represented by the ratio of doxorubicin IC50 in the absence and presence of verapamil and analogues (solid bars). The verapamil concentrations used were the minimal cytotoxic concentrations (IC20)-The compounds used were verapamil (1) ...

S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells, Eur. J. Cancer 1993, 30, 1377-1383. 

Kudoh K et al. Monitoring the expression profiles of doxorubicin-induced and doxombicin-resistant cancer cells by cDNA microarray. Cancer Res 2000 60 4161-4166. 

Andersen, A., Warren, D J., and Slordal, L. 1993. A sensitive and simple high performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit. 15 455. 

What is the average intravenous dose of Adriamycin (doxorubicin) for a child whose weight is 50 kg and height is 142 cm The average intravenous dose of doxorubicin for a child is 30 mg/m2. 

Bellamy, W.T., Dalton, W.S., Kailey, J.M., Gleason, M.C., McCloskey, T.M., Dorr, R. T. and Alberts, D.S. (1988) Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma... 

Green PS, Leeuwenburgh C (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochimica et Biophysica Acta-Molecular Basis of Disease 1588 94-101. 

Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23 7018-7030. 

Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16 1564-1569. 

Minchin RF, Johnston MR, Aiken MA, Boyd MR (1984) Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Exp Ther 229 193-198. 

Further investigations revealed that the superior antitumor efficacy of Leu-DOX was, indeed, due to site-selective activation and delivery of doxorubicin. At equitoxic intravenous doses of DOX and Leu-DOX (8 and 28 mg/kg, respectively, see above), the plasma levels of DOX attained were comparable, whereas differences were seen in tumor tissue concentrations [51]. The enzymes involved in the tumor-selective activation of Leu-DOX were not identified, although possible candidates include the cathepsin family of proteases [47],... 

Interestingly, a closely related prodrug of doxorubicin that has the same spacer (i.e., 6.33) was found to be a good substrate for plasmin while being stable in buffer and blood serum [55], A marked selectivity was seen against a plasmin-generating MCF-7 breast cancer cell line. 

G. M. Dubowchik, R. A. Firestone, Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin , Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346. 

Aich P, Sen R, Dasgupta D (1992b) Role of magnesium ion in the interaction between chromomycin A3 and DNA binding of chromomycin A3 — Mg + complexes with DNA. Biochemistry 31 2988-2997 Akman SA, Doroshow JJH, Thomas G, Burke J, Dizdaroglus M (1992) DNA base modifications induced in isolated human chromatin by NADH de hydrogenase-catalyzed reduction of doxorubicin. Biochemistry, 31 3500-3506... 

---